|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Medical versus surgical interventions for open angle glaucomaBurr J, Azuara-Blanco A, Avenell A
Bookmark this:
     more ...
SummaryMedications or surgery for the treatment of open angle glaucoma (OAG)Open angle glaucoma is the most common form of glaucoma and an important cause of blindness. Having a high intraocular pressure (IOP) is an important risk factor. Treatment for OAG aims to lower the IOP and thus reduce the risk of progressive loss of vision. Intraocular pressure can be lowered by medications (eye drops), laser therapy or surgery. There are many different types of eye drops available and these are compared in a recent Cochrane review (Vass 2007). Surgery for glaucoma has evolved in the last 40 years. The most common type is trabeculectomy, another type of operation involves inserting a tube, both types of surgery facilitate fluid drainage out of the eye. All these operations potentially lower the IOP, however, they may have complications during and after the operation and may fail in the long term due to scarring. Drainage surgery forms a 'bleb' i.e. small blister like elevation on the surface of the eye which can sometimes be uncomfortable. It is not clear whether medication or surgery is the better treatment for OAG. The purpose of this review was to review and assess evidence from randomised studies to compare treatment with medications with surgery in terms of how well they work, their relative safety and cost-effectiveness. Four relevant trials were identified, treating 888 people. Three studies were in the UK and one in the US. These trials had been initiated over many years from 1968 up to the most recent trial in 1993. The earlier trials used medications, and in one trial surgical techniques, that are now rarely used. Findings of these studies suggest that, in mild OAG, worsening of the condition was not different whether first treatment was medication or surgery, but surgery was associated with more eye discomfort, an increased risk of cataract and a slight reduction in distance vision at five years. In more severe glaucoma, surgery lowered IOP significantly more than medications (not widely used anymore) and reduced the risk of progressive loss of visual field. In three trials the risk of developing cataract was higher with surgery (trabeculectomy). There was insufficient evidence to determine how well more recently available medications work compared with surgery in more severe OAG, and which was the more cost-effective treatment option. More research is required.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2009 Issue 4, Copyright © 2009 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
April 20. 2005 AbstractBackgroundOpen angle glaucoma (OAG) is a common cause of blindness. ObjectivesTo study the relative effects of medical and surgical treatment of OAG. Search strategyWe searched CENTRAL, MEDLINE, EMBASE, LILACS, BIOSIS, SIGLE, NRR, CINAHL, ZETOC to April 2007, reference lists of articles and also contacted researchers in the field. Selection criteriaWe included randomised controlled trials comparing medications with surgery in adults. Data collection and analysisTwo authors independently assessed trial quality and extracted data. We contacted trial investigators for missing information. Main resultsFour trials involving 888 participants with previously untreated OAG were included. Surgery was Scheie's procedure in one trial and trabeculectomy in three trials. In three trials, primary medication was usually pilocarpine, in one trial a beta-blocker. In more severe OAG there is some evidence, from three trials, that medication was associated with more progressive VF loss and 6 to 9 mmHg less intraocular pressure (IOP) lowering than surgery. In the longer-term (two trials) the risk of failure of the randomised treatment was greater with medication than trabeculectomy (OR 3.90, 95% CI 1.60 to 9.53; HR 7.27, 95% CI 2.23 to 25.71). Medications and surgery have evolved since these trials were undertaken. In three trials the risk of developing cataract was higher with trabeculectomy (OR 2.69, 95%% CI 1.64 to 4.42). Methodological weaknesses were identified in all the trials. Authors' conclusionsEvidence from one trial suggests, for mild OAG, that the risk of glaucoma progression up to five-years is not significantly different whether treatment is initiated with medication or trabeculectomy. Reduced vision, cataract and eye discomfort are more likely with trabeculectomy. There is some evidence, for more severe OAG, that initial medication (pilocarpine, now rarely used as first line medication) is associated with a greater risk of glaucoma progression than surgery. Surgery lowers IOP more than medication. There was no evidence to determine the effectiveness of contemporary medication (prostaglandin analogues, alpha2-agonists and topical carbonic anhydrase inhibitors) compared with surgery in severe OAG, and in people of black ethnicity. More research is required. |